GUD Knight Therapeutics Inc.

7.892USD11.29 CAD · TSX-2.34%Mkt Cap: 775.62M USDP/E: 70.56

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refr…

Insiders, last 90 days12 buys
Institutional holders10 on file

Key Statistics

Company
Market Cap775.62M USD
Enterprise Value695.72M USD
Revenue (TTM)393.87M USD
Gross Profit139.97M USD
Net Income (TTM)-3.76M USD
Revenue/Share4.00 USD
Last Price7.892 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees830
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINCA4990531069
Valuation
P/E (Trailing)70.56
P/E (Forward)47.04
PEG—
EV/EBITDA11.19
EV/Revenue1.77
P/S1.97
P/B1.40
EPS (TTM)0.11 USD
EPS (Forward)0.17 USD
52W Range
3.95786% of range8.518
52W High8.518 USD
52W Low3.957 USD
Profitability
Gross Margin44.49%
Oper. Margin5.55%
EBITDA Margin15.78%
Profit Margin-1.19%
ROE-0.70%
ROA-0.51%
ROIC-0.25%
ROCE-0.27%
Growth
Revenue Growth13.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF48.20M USD
CapEx (TTM)23.55M USD
FCF Margin15.78%
FCF Yield8.02%
Net Debt-79.91M USD
Net Debt/EBITDA-1.29
Net Debt/FCF-1.29
Balance Sheet
Debt/Equity0.10
Current Ratio2.40
Quick Ratio1.61
Book Value/Sh5.66 USD
Cash/Share1.05 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.157 USD
Upside (mean)+16.0%
Target Range8.913 USD – 9.787 USD
8.913+16.0% to mean9.787
# Analysts7
Ownership
Shares Out.98.28M
Float60.64M
Insiders46.00%
Institutions18.61%
Short Interest
Short Ratio15.6d
Short % Out.1.00%
Shares Short979.50K
Short (prev mo.)1.21M
Technical
SMA 507.631 (+3.4%)
SMA 2006.223 (+26.8%)
Beta0.02
S&P 52W Chg12.00%
Avg Vol (30d)70.43K
Avg Vol (10d)86.82K
Technical Indicators
RSI (14)46.6
MACD0.2092
MACD Signal0.2770
MACD Hist.-0.0678
BB Upper8.501 USD
BB Middle8.094 USD
BB Lower7.688 USD
BB Width10.04%
ATR (14)0.2163 USD
Vol Ratio (20d)1.38x

About Knight Therapeutics (TSE: GUD)

›

Knight Therapeutics (TSE: GUD) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 830 employees.

The shares were at 11.29 CAD on 19 November 2026, up 86.0% over 52 weeks. Its 52-week range is 5.660 CAD to 12.19 CAD: the price is 7.3% below the high and 99.5% above the low.

At a market capitalisation of 1.11B CAD, it trades at 70.6 times trailing earnings and 47.0 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a premium of 186% for GUD.

Knight Therapeutics reports return on equity of -0.7%, an operating margin of 5.6% and revenue up 13.3% year over year.

It holds more cash than debt, a net cash position of 114.31M CAD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 7 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 13.10 CAD is 16.0% above the current price. The next earnings report is expected on 18 March 2027.